<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347808">
  <stage>Registered</stage>
  <submitdate>4/12/2011</submitdate>
  <approvaldate>7/12/2011</approvaldate>
  <actrnumber>ACTRN12611001255976</actrnumber>
  <trial_identification>
    <studytitle>Assessment of venous thromboembolic disease (VTE) in medical patients who presented to the Launceston General Hopspital (LGH)</studytitle>
    <scientifictitle>Assessment of venous thromboembolic disease (VTE) in medical patients who presented to the Launceston General Hopspital (LGH)</scientifictitle>
    <utrn>None</utrn>
    <trialacronym>VTE in Medical patients</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous thromboembolism (VTE) among medical patients.</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To assess the prevalence of venous thromboembolism (VTE) among medical patients.
Via assessment of all ulterasound or scans performed at the LGH for medical patients. The observation time is 6 months.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Venous thromboembolism (VTE).
Assessed by ultrasound or VQ-scan or CT-pulmonary angiogram</outcome>
      <timepoint>This timepoint will be assessed continously until the end of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess risk factors of VTE
Via correlation with the international criteria of VTE-risk with clinical assessments as well as radiological findings and labortaory tests.</outcome>
      <timepoint>This timepoint will be assessed continously until the end of the study.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Medical patients with documented VTE from both sexes</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>None</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/09/2012</actualenddate>
    <samplesize>1200</samplesize>
    <actualsamplesize>986</actualsamplesize>
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Clifford Craig Medical Trust Fund</primarysponsorname>
    <primarysponsoraddress>Level 5
Launceston General Hospital
Charles street
Launceston, Tasmania 7250
Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Launceston General Hospital</fundingname>
      <fundingaddress>Charles street
Launceston, Tasmania 7250
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate all medical patients who potentially at risk of developing blood clots (venous thrombo-embolism [VTE]) at any age group who are treated at the Launceston General hospital (LGH). 

We will study all factors that may influence clot formation such as Age, Weight, Gender, Mobility, presence of co-morbidities, presence of cancer, Personal history of VTE, Family history of VTE, other risk factors for VTE, additional laboratory markers such as blood count, coagulation study. 

The data of the trial will help to understand and know the risk factors for developing clots (VTE) among medical patients. 

This trial has the potential to change the treatment approach and the preventive strategies for medical patients in order to improve outcome and benefit all patients avoiding a relatively common VTE-complications of the treatment. 

This trial also reviewing the current protocols for prevention of VTE during the treatment of medical patients.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmanian Human Research Ethics Committee</ethicname>
      <ethicaddress>University of Tasmania
Private Bag 01
Hobart, Tas 7001
Australia</ethicaddress>
      <ethicapprovaldate>24/10/2011</ethicapprovaldate>
      <hrec>H12113</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>A/Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital
Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Afghanistan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>A/Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital
Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>A/Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital
Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Alhossain A. Khalafallah </name>
      <address>Launceston General Hospital Charles Street, Launceston, TAS 7250  </address>
      <phone>+61373487111  </phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au  </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>